On July 16, CSPC Pharmaceutical rose 3.08% in regular trading, trading at 8.52 HKD/share, with turnover of approximately 208 million HKD. The rally was driven by a cluster of positive developments including a breakthrough therapy designation and continued institutional buying.

On July 14, the company announced that its proprietary albumin-bound docetaxel combined with anbenitamab received breakthrough therapy designation from China's NMPA for the first-line treatment of unresectable or metastatic HER2-positive adult breast cancer. The designation followed positive Phase 3 results demonstrating significantly improved progression-free survival versus standard-of-care, with the company planning a near-term NDA submission.

On the institutional front, Huatai-PineBridge Fund purchased 7.368 million shares at approximately 8.14 HKD per share, totaling about 59.96 million HKD, while Orient Securities added 5.656 million shares at around 8.29 HKD. Additionally, the company recently received a $25 million R&D milestone payment from AstraZeneca under their strategic collaboration agreement for long-acting peptide drug development.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)